KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) EPS (Basic) (2016 - 2025)

Regeneron Pharmaceuticals has reported EPS (Basic) over the past 17 years, most recently at $8.24 for Q4 2025.

  • Quarterly results put EPS (Basic) at $8.24 for Q4 2025, down 3.51% from a year ago — trailing twelve months through Dec 2025 was $43.15 (up 5.53% YoY), and the annual figure for FY2025 was $43.07, up 5.31%.
  • EPS (Basic) for Q4 2025 was $8.24 at Regeneron Pharmaceuticals, down from $14.09 in the prior quarter.
  • Over the last five years, EPS (Basic) for REGN hit a ceiling of $29.51 in Q2 2021 and a floor of $6.7 in Q1 2024.
  • Median EPS (Basic) over the past 5 years was $10.74 (2023), compared with a mean of $11.9.
  • Biggest five-year swings in EPS (Basic): skyrocketed 260.32% in 2021 and later crashed 73.23% in 2022.
  • Regeneron Pharmaceuticals' EPS (Basic) stood at $20.98 in 2021, then crashed by 46.57% to $11.21 in 2022, then decreased by 2.85% to $10.89 in 2023, then dropped by 21.58% to $8.54 in 2024, then decreased by 3.51% to $8.24 in 2025.
  • The last three reported values for EPS (Basic) were $8.24 (Q4 2025), $14.09 (Q3 2025), and $13.24 (Q2 2025) per Business Quant data.